Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Low Anti-SARS-CoV-2 S Antibody Levels Predict Increased Mortality

By LabMedica International staff writers
Posted on 20 Oct 2021
Anti-SARS-CoV-2 spike (S) antibodies bind to multiple domains in this viral protein. More...
Host antibodies directed at the receptor binding domain (RBD) mediate inhibition of viral attachment to cell surface receptors.

Anti-S antibodies could play a role in reducing viral replication during an ongoing acute infection by interfering with virus entry into a cell. Interestingly, whether levels of host-produced endogenous antibodies against the S protein could influence mortality risk in severe COVID-19 has not been sufficiently studied.

A large team of medical scientists associated with the Instituto de Salud Carlos III (Madrid, Spain) recruited 92 critically ill adult patients with a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 from 16th March to 15th April 2020, during the first pandemic wave from several hospitals. They obtained EDTA plasma in the first 24 hours following admission to the Intensive Care Unit (ICU).

The scientists quantified SARS-CoV-2 RNA in plasma using the Bio-Rad SARS-CoV-2 droplet digital PCR kit (Bio-Rad, Hercules, CA, USA). The team developed a specific immunoassay to quantify anti-SARS-CoV-2 S IgG and IgM antibodies in plasma and evaluated the presence/absence of N antigen of SARS-CoV-2 in plasma using the Panbio COVID-19 Ag Rapid Test Device (Abbott, Chicago, IL, USA).

The investigators reported that the frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Ten patients (of the total cohort) had no detectable levels in the plasma of anti-SARS-CoV-2 S IgG, and 13 had no detectable levels of anti-SARS-CoV-2 S IgM. Patients who died showed more often absence/lower levels of anti-SARS-CoV-2 S IgM and IgG than those who survived by day 30 following ICU admission. In contrast to that observed for antibodies, non-survivors showed more frequently the presence of antigenaemia along with higher viral RNA loads in plasma. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality. Viral RNA-load in plasma and N-antigenaemia predicted increased mortality.

Jesús F. Bermejo-Martin, MD, PhD, a Clinical Immunologist and a co-senior author of the study, said, “Our findings support that treatment with exogenous antibodies in COVID-19 should be personalized, reserving this therapy for those patients with absent or low endogenous antibodies levels.”

The authors concluded that low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19 and their findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2. The study was published on October 5, 2021 in the Journal of Internal Medicine.

Related Links:
Instituto de Salud Carlos III
Bio-Rad
Abbott



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.